Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Not Recruiting

Trial ID: NCT03833167


This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

Stanford Investigator(s)

Anne Lynn S. Chang, MD
Anne Lynn S. Chang, MD

Professor of Dermatology


Inclusion Criteria:

   - Has histologically confirmed cutaneous squamous cell carcinoma (cSCC) as the primary
   site of malignancy (metastatic skin involvement from another type of primary cancer or
   from an unknown primary cancer is not permitted)

   - Has histologically confirmed LA cSCC with ≥1 high-risk feature(s) as the primary site
   of malignancy

   - Has undergone complete macroscopic resection of all known cSCC disease with or without
   microscopic positive margins. For those participants with residual microscopic
   positive margin involvement, confirmation that additional re-excision is not possible
   must be provided

   - Has completed adjuvant radiotherapy (RT) for LA cSCC with last dose of RT ≥4 weeks and
   ≤16 weeks from randomization

   - Has received an adequate post-op dose of RT (either hypofractionated or conventional)

   - Is disease free as assessed by the investigator with complete radiographic staging
   assessment ≤28 days from randomization

   - Is not pregnant or breastfeeding

   - Is not a person of childbearing potential (POCBP)

   - Has a negative pregnancy test ≤72 hours before the first dose of study intervention.

   - Has provided an archival or newly-obtained tumor tissue sample adequate for Programmed
   Cell Death Ligand 1 (PD-L1) testing as determined by central laboratory testing

   - Has a life expectancy of >3 months

   - Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ≤10 days
   prior to the first dose of study intervention.

Exclusion Criteria:

   - Has macroscopic residual cSCC after surgery and/or recurrence with active cSCC disease
   before randomization

   - Has any other histologic type of skin cancer other than invasive cSCC (eg, basal cell
   carcinoma) that has not been definitively treated with surgery or radiation; Bowen's
   disease; Merkel cell carcinoma; or melanoma

   - Has received prior therapy with an anti-programmed cell death receptor 1(PD-1),
   anti-PD-L1, or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an
   agent directed to another costimulatory or coinhibitory T-cell receptor (eg, cytotoxic
   T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)

   - Has received prior systemic anticancer therapy including investigational agents for
   cSCC ≤4 weeks prior to before start of study intervention.

   - Has not recovered from all radiation-related toxicities and has not had radiation

   - Has received a live vaccine ≤30 days prior to the first dose of study intervention

   - Has received an investigational agent or has used an investigational device within 4
   weeks prior to the first dose of study treatment.

   - Has known additional malignancy that is progressing or has required active treatment
   within the past 2 years. Note: Participants with basal cell carcinoma of the skin,
   squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ
   of the bladder, that have undergone potentially curative therapy are not excluded.
   Other exceptions may be considered with Sponsor consultation. Note: Participants with
   low risk early-stage prostate cancer defined as below are not excluded: Stage T1c or
   T2a with a Gleason score ≤6 and a prostate-specific antigen (≤10 ng/ml) either treated
   with definitive intent or untreated in active surveillance that has been stable for
   the past year prior to study allocation. Early stage asymptomatic CLL without prior
   treatment and without any of the risk features (unmutated IGHV, lymphocytes >15,000μL,
   palpable lymph nodes) will be eligible for the study

   - Has an active autoimmune disease that has required systemic treatment in past 2 years
   except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid).

   - Has a history of (noninfectious) pneumonitis/interstitial lung disease that required
   steroids or has current pneumonitis/interstitial lung disease

   - Has an active infection requiring systemic therapy

   - Has a known history of human immunodeficiency virus (HIV) infection

   - Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]
   reactive) or known active hepatitis C virus (HCV; defined as HCV RNA [qualitative] is
   detected) infection

   - Is pregnant or breastfeeding or expecting to conceive or father children within the
   projected duration of the study, starting with the screening visit through 120 days
   after the last dose of study intervention

   - Has had an allogeneic tissue/solid organ transplant


biological: Pembrolizumab 400 mg

drug: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Alexander Valencia

New Trial Alerts